% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

big_pharma_coming 4 posts  |  Last Activity: Oct 6, 2015 11:36 AM Member since: Oct 4, 2011
  • big_pharma_coming by big_pharma_coming Oct 6, 2015 11:36 AM Flag

    Recommendations Alert on EXAS

    See the research on

    News Breaks

    October 6, 2015

    09:40 EDT


    Exact Sciences weakness a buying opportunity, says Craig-Hallum

    Craig-Hallum recommends buying Exact Sciences on weakness related to the disappointing outcome from the USPSTF draft recommendation on colon cancer screening. Analyst Bill Bonello continues to believe Cologuard will be standard of care for colon cancer screening and said the Task Force recommendation will not impact Medicare coverage and Medicare alone is a $3.5B opportunity. Bonello rates shares a Buy and lowered his price target to $22 from $30.

    09:22 EDT


    On The Fly: Pre-market Movers

    UP AFTER EARNINGS: PepsiCo (PEP), up 2.6%. ALSO HIGHER: PMC-Sierra (PMCS), up 33.8% after being acquired by Skyworks (SWKS)... Skyworks is up 2.5%... MagneGas (MNGA), up 8.9% after receiving order from a U.S. Army contractor... Exelixis (EXEL), up 5.9% after the phase 3 pivotal trial of cobimetinib met its secondary endpoint... DuPont (DD), up 6.1% after CEO and chair Ellen Kullman retires... Mallinckrodt (MNK), up 3% after providing fiscal 2016 guidance and a business update in a conference call. LOWER: EXACT Sciences (EXAS), down 34.7% after Cologuard included as an alternative screen test under the U.S. Preventive Services Task Force draft guidelines... Illumina (ILMN), down 17.7% after providing third quart er, fourth quarter, and fiscal 2015 guidance... Tesla (TSLA), down 2.5% after Model X forecasts were lowered at Morgan Stanley and the firm cut its price target to $450.

    08:39 EDT


    Exact Sciences to host conference call

    Conference call to discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening will be held on October 6 at 9 am. Webcast Link

    07:44 EDT


    Exact Sciences downgraded to Hold from Buy at Benchmark

    Benchmark analyst Jan Wald downgraded Exact Sciences to Hold after the U.S. Preventative Services Task Force declined to give Cologuard an "A" or "B" rating, describing the test as an Alternative Test. Wald calls the development "bad news" and cut her price target for Exact shares to $11 from $34.

    07:24 EDT


    Exact Sciences should be bought on the open, says Jefferies

    Jefferies analyst Brandon Couillard views the selloff in shares of Exact Sciences following the U.S. Preventive Services Task Force draft recommendation for colorectal cancer screening as overdone. In a departure from its former grade-based rating system, the panel deemed stool DNA testing, which is used by Exact's Cologuard, as a second tier "alternative" test, Couillard tells investors in a research note. While the pathway for private payor reimbursement may now be lower and slower for Cologuard, the initial after-hours selloff appears overdone, the analyst writes. He recommends buying shares of Exact Sciences on the open. "Considerable" short covering, which 27% of float sold short , should offer support for the stock, the analyst argues. He keeps a Buy rating on the Exact with a $35 price target. The stock is down 34%, or $6.25, to $12.28 in pre-market trading.

    07:07 EDT


    Exact Sciences price target lowered to $14 from $25 at Stephens

    Stephens analyst Drew Jones lowered his price target on Exact Sciences to $14 from $25 following the preliminary decision from the U.S. Preventive Services Task Force on colorectal cancer screening. Cologuard was not included as a "recommended" test but instead as an "alternative test" and Jones believes an A/B designation from USPSTF is essential for broad coverage of Exact Sciences' test. The analyst, who keeps an Equal Weight rating on the stock, noted, however, that this preliminary decision will now be followed by a 30-day comment period.

    05:13 EDT


    Cologuard included as alternative screen test under draft USPSTF guidelines

    Exact Sciences issued the following statement following the U.S. Preventive Services Task Force, or USPSTF, draft recommendation statement for colorectal cancer screening. USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an "A" rating for colorectal cancer screening starting at age 50 and continuing until age 75. Screening for individuals age 75 through 85 is graded a "C." This approach represents a change from the 2008 recommendations, which assigned specific grades for different tests, including an "I" rating for stool-based DNA. Cologuard is a non-invasive, FDA-approved col orectal cancer screening test that is covered by Medicare. Cologuard specifically and sDNA generally are included in the American Cancer Society and the U.S. Multi-Society Task Force screening guidelines, which include the American Gastroenterological Association, American College of Gastroenterolgy and American Society for Gastrointestinal Endoscopy. Following USPSTF's 30-day public comment period, a final recommendation is expected to be announced in 2016.

  • big_pharma_coming big_pharma_coming Sep 21, 2015 10:09 AM Flag

    You are not exaggerating - this article puts it all together. If you are short ZIOP - cover. If you are long - go longer....Kirk was in EU....rumors multiple companies interested in buying or partnering with ZIOP. Merck Germany, Novartis, Roche, GSK and AZN....who knows but after brain cancer data in Nov this is $20-$25 agree that a ZIOP takeover just went up to $40 minimum a share

  • 3 webcasts in next 2 wks...ADDED...
    Wednesday, September 9, 2015 at Baird's 2015 Healthcare Conference in New York City at 3:45 pm ET

    Wednesday, September 16, 2015 at the 2015 Morgan Stanley Global Healthcare Conference in New York City at 1:40 pm ET

    Thursday, September 17, 2015 at the 2015 Bank of America Merrill Lynch Global Healthcare Conference in London at 8 am ET

  • big_pharma_coming big_pharma_coming Jul 27, 2015 3:07 PM Flag

    Awesome news really.....means very early interim data is good....this definitely could be a Ph 2 approval nothing works in brain cancer

11.12-0.06(-0.54%)Oct 8 4:00 PMEDT